title: Topical interferon alfa-2b for management of ocular surface squamous neoplasia in 23 cases: outcomes based on American Joint Committee on Cancer classification.
abstract: OBJECTIVE
  To evaluate the efficacy of topical interferon alfa-2b in the management of ocular surface squamous neoplasia (OSSN).
  
  
  METHODS
  Clinically visible OSSN in 20 patients (23 tumors) was managed with topical interferon alfa-2b, 1 million IU/mL, 4 times daily. Tumor control and complications were evaluated according to American Joint Committee on Cancer classification.
  
  
  RESULTS
  Complete tumor resolution was achieved in 19 tumors (83%) following topical interferon alfa-2b treatment for a median period of 6 months (mean, 7 months; range, 1-12 months) and maintained for up to 24 months of follow-up. Of the 4 tumors with partial resolution (17%), tumor surface area was reduced 44% (median) during 4 months (median) without further response and alternative therapy was used. Based on American Joint Committee on Cancer classification, complete control was achieved in 2 of 3 Tis (67%), 17 of 20 T3 (85%), 19 of 23 N0 (83%), and 19 of 23 M0 (83%) category tumors. Tumors involving the cornea responded earlier compared with those without corneal involvement (P = .01). Initial tumor size did not correlate with time to response (P = .27). Recurrence was noted in 1 case (Tis, 4%) at 3 months. Adverse effects included conjunctival hyperemia (2 [10%]), follicular hypertrophy (2 [10%]), giant papillary conjunctivitis (1 [5%]), irritation (1 [5%]), corneal epithelial defect (1 [5%]), and flulike symptoms (1 [5%]); all resolved within 1 month of medication discontinuation.
  
  
  CONCLUSIONS
  According to American Joint Committee on Cancer classification, complete control with topical interferon alfa-2b can be achieved in 67% of Tis, 85% of T3, and 83% of all OSSN.
authors.affiliation: The Ocular Oncology Service, Wills Eye Institute, Thomas Jefferson University, Philadelphia, Pennsylvania 19107, USA.
authors.forename: Sanket U
authors.initials: SU
authors.lastname: Shah
authors.forename: Swathi
authors.initials: S
authors.lastname: Kaliki
authors.forename: H Jane
authors.initials: HJ
authors.lastname: Kim
authors.forename: Sara E
authors.initials: SE
authors.lastname: Lally
authors.forename: Jerry A
authors.initials: JA
authors.lastname: Shields
authors.forename: Carol L
authors.initials: CL
authors.lastname: Shields
mesh_terms: D000287:Administration, Topical; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002278:Carcinoma in Situ / Q000145:classification / Q000188:drug therapy* / Q000473:pathology; D002294:Carcinoma, Squamous Cell / Q000145:classification / Q000188:drug therapy* / Q000473:pathology; D003230:Conjunctival Neoplasms / Q000145:classification / Q000188:drug therapy* / Q000473:pathology; D003316:Corneal Diseases / Q000145:classification / Q000188:drug therapy* / Q000473:pathology; D005134:Eye Neoplasms / Q000145:classification / Q000188:drug therapy* / Q000473:pathology; D005260:Female; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D011994:Recombinant Proteins / Q000009:adverse effects / Q000627:therapeutic use; D012074:Remission Induction; D016896:Treatment Outcome; D014792:Visual Acuity; D055815:Young Adult
chemical_list: D000970:Antineoplastic Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins